Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management.

Published online

Journal Article (Review)

Aromatase inhibitors are widely used as adjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer. While the agents are associated with slightly improved survival outcomes when compared to tamoxifen alone, bone and musculoskeletal side effects are substantial and often lead to discontinuation of therapy. Ideally, the symptoms should be prevented or adequately treated. This review will focus on bone and musculoskeletal side effects of aromatase inhibitors, including osteoporosis, fractures, and arthralgias. Recent advances have been made in identifying potential mechanisms underlying these effects. Adequate management of symptoms may enhance patient adherence to therapy, thereby improving breast cancer-related outcomes.

Full Text

Duke Authors

Cited Authors

  • Gaillard, S; Stearns, V

Published Date

  • March 14, 2011

Published In

Volume / Issue

  • 13 / 2

Start / End Page

  • 205 -

PubMed ID

  • 21457526

Pubmed Central ID

  • 21457526

Electronic International Standard Serial Number (EISSN)

  • 1465-542X

Digital Object Identifier (DOI)

  • 10.1186/bcr2818

Language

  • eng

Conference Location

  • England